Additionally, in MASLD overall, or specifically in MASH, there was significantly lower plasma adiponectin and higher plasma retinol-binding protein-4 compared to NLO, and C-reactive protein was significantly higher in those with MASH, whereas fibroblast growth factor (FGF)−19 was significantly lower in those with MASLD compared to NLO. This evidence concerns the gene FGF19 and metabolic dysfunction-associated steatotic liver disease.